1-3 of 3
Marie-Laure Casadebaig Bravo
Close
Sort by
Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Marek Trneny, Thierry Lamy, MDPhD, Jan Walewski, MD PhD, David Belada, MD PhD, Jiri Mayer, John A Radford, MB ChB, MRCP, MD FRCP, Wojciech Jurczak, MD PhD, Franck Morschhauser, Julia Alexeeva, MD, Simon A. Rule, MD, Boris V Afanasyev, Professor, Kamil Kaplanov, Antoine Thyss, MD, Alexej Kuzmin, MD, Sergey Voloshin, MD, Kazimierz Kuliczkowski, prof., Agnieszka Giza, MD, Noel Milpied, MD PhD, Caterina Stelitano, MD, Reinhard Marks, MD, Lorenz Trümper, MD, Tsvetan Biyukov, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Luca Arcaini, MD
Journal: Blood
Blood (2016) 128 (22): 2978.
https://doi.org/10.1182/blood.V128.22.2978.2978
Published: 2016
Journal Articles

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael Wang, MD, Peter Martin, MD, Tycel Phillips, MD, Andre Goy, MD, Izidore S Lossos, MD, Simon A. Rule, MD, Mehdi Hamadani, MD, Nilanjan Ghosh, MD PhD, Craig B. Reeder, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 1786.
https://doi.org/10.1182/blood.V128.22.1786.1786
Published: 2016
Journal Articles

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, MD, Jiri Mayer, Prof., MD PhD, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
Journal: Blood
Blood (2014) 124 (21): 626.
https://doi.org/10.1182/blood.V124.21.626.626
Published: 2014